Solid Tumor Oncology Education Foundation Sponsors Free Local Seminars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

SECAUCUS, NJ--To accommodate community-based physicians who may not be able to attend national professional meetings, the newly formed not-for-profit Solid Tumor Oncology Education Foundation, Inc. will sponsor a series of free local seminars and audioconferences, led by a faculty of expert physicians.

SECAUCUS, NJ--To accommodate community-based physicians who maynot be able to attend national professional meetings, the newlyformed not-for-profit Solid Tumor Oncology Education Foundation,Inc. will sponsor a series of free local seminars and audioconferences,led by a faculty of expert physicians.

The programs will focus on breast, colorectal, gastrointestinal,genitourinary, gynecologic, pancreatic, and lung cancers, andinclude such subjects as adjuvant and palliative therapy, currentand new protocol regimens, screening and diagnosis, and quality-of-lifeissues.

Beginning this month, the Foundation will offer a series of presentationsconducted at local, state, and regional oncology meetings by leadingoncolo-gists, as well as telephone audioconfer-ences, allowinghealth-care professionals to participate from their home or office.

The chairman of the Foundation is Paul A. Bunn, Jr., MD, Universityof Colorado Cancer Center. Board members are Laurence H. Baker,DO, University of Michigan Comprehensive Cancer Center; GabrielN. Hortobágyi, MD, University of Texas M.D. Anderson CancerCenter; John S. Macdonald, MD, Temple University Cancer Center;Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, and ElizabethJ. Shpall, MD, University of Colorado Health Sciences Center.

The formation of the Foundation was made possible by an unrestrictededucational grant from Lilly Oncology. Oncolo-gists can get moreinformation by calling 1-800-223-8978.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content